Cabaletta Bio

Philadelphia, United States

Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.

May 2026

Post-IPO Equity

Biotechnology Health Care Medical Robotics Therapeutics

Top Investors

Eli LillyCormorant Asset ManagementAdage Capital ManagementRedmile GroupBain Capital Life Sciences

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Cabaletta Bio

Who are Cabaletta Bio's investors?

Cabaletta Bio's investors include Eli Lilly, Cormorant Asset Management, Adage Capital Management, Redmile Group, Bain Capital Life Sciences.

Where is Cabaletta Bio headquartered?

Cabaletta Bio is headquartered in Philadelphia, United States.

What does Cabaletta Bio do?

Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.

What stage is Cabaletta Bio at?

Cabaletta Bio is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated May 4, 2026.

MLA

"Cabaletta Bio — Funding & Investors." VCBacked, May 4, 2026, https://www.vcbacked.co/company/cabaletta-bio. Accessed June 3, 2026.

APA

VCBacked. (2026). Cabaletta Bio — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/cabaletta-bio

Wikipedia (cite web)

{{cite web |title=Cabaletta Bio — Funding & Investors |url=https://www.vcbacked.co/company/cabaletta-bio |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated May 4, 2026.

Similar Companies in Biotechnology